ARREST Trial: Precision Radiation Boosts to Fix 177Lu-PSMA’s 50% Failure Rate
ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically. Current 177Lu-PSMA therapy […]
